JP2019515648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515648A5 JP2019515648A5 JP2018545380A JP2018545380A JP2019515648A5 JP 2019515648 A5 JP2019515648 A5 JP 2019515648A5 JP 2018545380 A JP2018545380 A JP 2018545380A JP 2018545380 A JP2018545380 A JP 2018545380A JP 2019515648 A5 JP2019515648 A5 JP 2019515648A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- antibody
- seq
- sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 89
- 239000000427 antigen Substances 0.000 claims description 62
- 102000036639 antigens Human genes 0.000 claims description 62
- 108091007433 antigens Proteins 0.000 claims description 62
- 210000004027 cell Anatomy 0.000 claims description 56
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 45
- 102000040430 polynucleotide Human genes 0.000 claims description 26
- 108091033319 polynucleotide Proteins 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 26
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 23
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims description 12
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 claims description 12
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims description 12
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 12
- 230000026731 phosphorylation Effects 0.000 claims description 12
- 238000006366 phosphorylation reaction Methods 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 12
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 102000000704 Interleukin-7 Human genes 0.000 claims description 8
- 108010002586 Interleukin-7 Proteins 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 238000002405 diagnostic procedure Methods 0.000 claims description 8
- 102000049284 human IL7R Human genes 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 6
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 claims description 4
- 230000006044 T cell activation Effects 0.000 claims description 4
- 238000004873 anchoring Methods 0.000 claims description 4
- 102000052622 human IL7 Human genes 0.000 claims description 4
- 102000045535 human TSLP Human genes 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000004068 intracellular signaling Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000013066 combination product Substances 0.000 claims description 3
- 229940127555 combination product Drugs 0.000 claims description 3
- 238000002648 combination therapy Methods 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 claims description 2
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 230000005890 cell-mediated cytotoxicity Effects 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 238000011002 quantification Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000004940 costimulation Effects 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301271P | 2016-02-29 | 2016-02-29 | |
| US62/301,271 | 2016-02-29 | ||
| PCT/IB2017/000293 WO2017149394A1 (en) | 2016-02-29 | 2017-02-28 | Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515648A JP2019515648A (ja) | 2019-06-13 |
| JP2019515648A5 true JP2019515648A5 (enExample) | 2020-04-16 |
| JP7053479B2 JP7053479B2 (ja) | 2022-04-12 |
Family
ID=58530580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545380A Active JP7053479B2 (ja) | 2016-02-29 | 2017-02-28 | ＩＬ７受容体細胞外ドメインα鎖に対する非拮抗性抗体及び癌治療におけるそれらの使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11230602B2 (enExample) |
| EP (1) | EP3423496B1 (enExample) |
| JP (1) | JP7053479B2 (enExample) |
| KR (1) | KR102819051B1 (enExample) |
| CN (1) | CN109195987B (enExample) |
| AU (1) | AU2017225495B2 (enExample) |
| BR (1) | BR112018067479A2 (enExample) |
| CY (1) | CY1122072T1 (enExample) |
| DK (1) | DK3423496T3 (enExample) |
| ES (1) | ES2737307T3 (enExample) |
| HR (1) | HRP20191445T1 (enExample) |
| HU (1) | HUE045183T2 (enExample) |
| IL (1) | IL261330B2 (enExample) |
| LT (1) | LT3423496T (enExample) |
| MA (1) | MA43767B1 (enExample) |
| MD (1) | MD3423496T2 (enExample) |
| ME (1) | ME03446B (enExample) |
| PL (1) | PL3423496T3 (enExample) |
| PT (1) | PT3423496T (enExample) |
| RS (1) | RS59223B1 (enExample) |
| SI (1) | SI3423496T1 (enExample) |
| SM (1) | SMT201900460T1 (enExample) |
| WO (1) | WO2017149394A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| WO2019043065A1 (en) * | 2017-08-29 | 2019-03-07 | Ose Immunotherapeutics | METHOD AND PREPARATION FOR SORTING T EFFECTOR LYMPHOCYTES USING ANTI-CD127 ANTIBODIES FOR CELL THERAPY APPLICATIONS |
| EP3790898A4 (en) * | 2018-05-10 | 2022-03-02 | Neuracle Science Co., Ltd | SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5, AND METHOD OF USE THEREOF |
| JP2022539753A (ja) * | 2019-06-28 | 2022-09-13 | ザ ユニバーシテイ オブ メルボルン | ガンマデルタｔ細胞を阻害する、または活性化させる方法 |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| CA3181394A1 (en) * | 2020-04-27 | 2021-11-04 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting cd127 and use thereof |
| WO2021236691A1 (en) * | 2020-05-18 | 2021-11-25 | Jumaa Weinacht Hassan | Composition for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| CA2655392A1 (en) | 2006-05-31 | 2007-12-06 | The Regents Of The University Of California | Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs |
| ATE542830T1 (de) | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| WO2010085643A1 (en) | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| PE20121702A1 (es) | 2010-01-28 | 2012-12-14 | Glaxo Group Ltd | Proteinas de enlace cd127 |
| SA114360064B1 (ar) | 2010-02-24 | 2016-01-05 | رينات نيوروساينس كوربوريشن | طرق وأجسام مضادة معارضة ضد مستقبل il-7 |
| EP2583980A1 (en) * | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| US20150297310A1 (en) | 2014-04-17 | 2015-10-22 | Georgia Regents Research Institute, Inc. | Methods for selecting a treatment for cancer |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
-
2017
- 2017-02-28 PL PL17716593T patent/PL3423496T3/pl unknown
- 2017-02-28 MA MA43767A patent/MA43767B1/fr unknown
- 2017-02-28 AU AU2017225495A patent/AU2017225495B2/en active Active
- 2017-02-28 JP JP2018545380A patent/JP7053479B2/ja active Active
- 2017-02-28 BR BR112018067479-6A patent/BR112018067479A2/pt active IP Right Grant
- 2017-02-28 EP EP17716593.3A patent/EP3423496B1/en active Active
- 2017-02-28 US US16/080,572 patent/US11230602B2/en active Active
- 2017-02-28 LT LTEP17716593.3T patent/LT3423496T/lt unknown
- 2017-02-28 PT PT17716593T patent/PT3423496T/pt unknown
- 2017-02-28 HU HUE17716593A patent/HUE045183T2/hu unknown
- 2017-02-28 HR HRP20191445 patent/HRP20191445T1/hr unknown
- 2017-02-28 ME MEP-2019-215A patent/ME03446B/me unknown
- 2017-02-28 KR KR1020187028377A patent/KR102819051B1/ko active Active
- 2017-02-28 CN CN201780014099.2A patent/CN109195987B/zh active Active
- 2017-02-28 IL IL261330A patent/IL261330B2/en unknown
- 2017-02-28 SI SI201730078T patent/SI3423496T1/sl unknown
- 2017-02-28 SM SM20190460T patent/SMT201900460T1/it unknown
- 2017-02-28 WO PCT/IB2017/000293 patent/WO2017149394A1/en not_active Ceased
- 2017-02-28 ES ES17716593T patent/ES2737307T3/es active Active
- 2017-02-28 DK DK17716593.3T patent/DK3423496T3/da active
- 2017-02-28 MD MDE20190066T patent/MD3423496T2/ro not_active IP Right Cessation
- 2017-02-28 RS RSP20190987 patent/RS59223B1/sr unknown
-
2019
- 2019-08-23 CY CY20191100905T patent/CY1122072T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515648A5 (enExample) | ||
| TWI701259B (zh) | ４﹘１ｂｂ抗體及其製備方法和應用 | |
| ES2975063T3 (es) | Anti-CD25 optimizado para FC para el agotamiento celular específico de tumores | |
| JP7549621B2 (ja) | Ｏ－アセチル化ＧＤ２ガングリオシド（ＯＡｃＧＤ２）に対するヒト化抗体 | |
| JP2026001061A (ja) | 抗ｄｌｌ３キメラ抗原受容体及びその使用 | |
| HRP20191445T1 (hr) | Ne-antagonistička antitijela usmjerena protiv alfa lanca izvanstanične domene il7 receptora i njihova uporaba u liječenju raka | |
| JP2021511818A (ja) | Ｖｉｓｔａ抗原結合性分子 | |
| EP3405494A1 (en) | Ror2 antibody compositions and related methods | |
| KR20210066865A (ko) | 키메라 항원 수용체 | |
| US20240018248A1 (en) | An ltbr agonist in combination therapy against cancer | |
| JP7584453B2 (ja) | Ｔａｃｉを標的とする抗体及びキメラ抗原受容体 | |
| JP2025063141A (ja) | 抗ｈＫ２キメラ抗原受容体（ＣＡＲ） | |
| US20250026836A1 (en) | Anti-hla-g antibodies | |
| JP2025170264A (ja) | 抗ｂｃｍａ剤のための投与レジメン | |
| WO2022117569A1 (en) | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer | |
| TW202233682A (zh) | 用於投與ＢＣＭＡｘＣＤ３結合分子之方法 | |
| TW202233677A (zh) | Bcma/taci抗原結合分子 | |
| KR102760955B1 (ko) | Gucy2c 결합 폴리펩타이드 및 그의 용도 | |
| KR102290335B1 (ko) | Cd30을 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
| CN118382455A (zh) | Her2变体car | |
| JP2023517889A (ja) | ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法 | |
| CN117377687A (zh) | 抗癌组合疗法中的ltbr激动剂 | |
| HK40101561A (zh) | 人ccr8结合剂 | |
| HK40103081A (zh) | 鼠交叉反应性人ccr8结合剂 | |
| HK40102183A (zh) | 非阻断性人ccr8结合剂 |